European drug regulator rejects Alzheimer’s treatment Leqembi from Biogen, Eisai
The committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreThe committee said Leqembi's effect on delaying cognitive decline does not outweigh "the risk of serious side effects associated with
Read MoreNovo Nordisk's Wegovy has received backing from the EU's medical regulator to expand the weight loss drug's use to reducing
Read MoreThe company plans to conduct studies in the second half of the year evaluating multiple doses of the drug. Source
Read MoreNvidia is a fan of Recursion Pharmaceuticals. Data expected from the company will help determine valuations for stocks using AI
Read MoreNovo Nordisk investors appeared unperturbed Thursday by a critical Harvard report that linked weight loss drugs to a rare eye
Read MoreIt's a long-awaited win for Eli Lilly after donanemab faced several delays in its path to the market, including an
Read MoreRite Aid used its bankruptcy to close hundreds of stores, sell its pharmacy benefit company Elixir, and negotiate settlements. Source
Read MoreDrugmakers showed off data on weight loss and diabetes drugs. Also, Oracle announced the general availability of AI documentation assistant
Read MorePresident Joe Biden has made lowering U.S. drug prices a key pillar of his health-care agenda and reelection platform for
Read More